QF 2004B | 221332-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: QF 2004B
• 英文别名: Unii-HB82hzf849；2-[[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]methyl]-1,2,3,9-tetrahydrocarbazol-4-one
• CAS: 221332-70-3
• 化学式: C₂₅H₂₄FN₃O₂
• 分子量: 417.483
• InChiKey: SPBXLWNNWOLJEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-hydroxymethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one 在 4-二甲氨基吡啶 作用下， 以 吡啶 、 N-甲基吡咯烷酮 为溶剂， 反应 72.0h， 生成 QF 2004B
  参考文献：
  名称：

  Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D2, 5-HT2A, 5-HT2B and 5-HT2C receptors

  摘要：

  We describe practical and efficient routes for synthesis of 2-aminomethyl-1,2,3,9-tetrahydro-4H-carbazol-4-ones using the Fischer indole synthesis or palladium-catalysed cyclization methodologies, as well as their affinities for D-2, 5-HT2A and 5-HT2C receptors, and their activity at the 5-HT2B receptor. The most active compounds, 4b (QF 2003B) and 4c (QF 2004B), with a pK(i) (5-HT2A/D-2) ratio of 1.28 show a potential antipsychotic profile according to Meltzer's classification. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00109-4

文献信息

• Butyrophenone analogues in the carbazole series: Synthesis and determination of affinities at D2 and 5-HT2A receptors
  作者：Christian F. Masaguer、Emilio Formoso、Enrique Raviña、Helena Tristán、M.Isabel Loza、Emilia Rivas、JoséAngel Fontenla

  DOI：10.1016/s0960-894x(98)00639-8

  日期：1998.12

  We describe a practical and efficient route for synthesis of 2-aminomethyl-1,2,3,9-tetrahydro-4H-carbazol-4-ones using an effective Fisher indole methodology. The most active compounds, 4b (QF 2003B) and 4c (QF 2003B), with pKi (5-HT2A/D-2) ratio of 1.28 show an antipsychotic profile according to Meltzer's classification, (C) 1998 Elsevier Science Ltd. All rights reserved.
• METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY
  申请人：Medivation Neurology, Inc.

  公开号：EP2175724A1

  公开（公告）日：2010-04-21
• [EN] METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY<br/>[FR] PROCÉDÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT DE LA SCHIZOPHRÉNIE PAR THÉRAPIE DE COMBINAISON D'ANTIPSYCHOTIQUES
  申请人：MEDIVATION NEUROLOGY INC

  公开号：WO2009017836A1

  公开（公告）日：2009-02-05

  The present invention relates to combination therapies and methods for treating, preventing and/or delaying the onset and/or development of schizophrenia, wherein the combination therapies comprise a hydrogenated pyrido[4,3 -b]indole or a pharmaceutically acceptable salt thereof, such as dimebon, and an antipsychotic.